CHEST X-RAY ASSESSMENT USING A DETAILED SCORING METHOD IN A RANDOMIZED TRIAL OF INFLIXIMAB IN SUBJECTS WITH CHRONIC PULMONARY SARCOIDOSIS

CHEST Journal ◽  
2005 ◽  
Vol 128 (4) ◽  
pp. 203S
Author(s):  
M. Kavuru ◽  
R.M. duBois ◽  
U. Costabel ◽  
M.A. Judson ◽  
M. Drent ◽  
...  
1990 ◽  
Vol 4 (8) ◽  
pp. 489-494 ◽  
Author(s):  
Gerry N Schep ◽  
Linda J Scully

A 43-year-old man with longstanding ulcerative colitis developed primary sclerosing cholangitis established by cholangiography and liver biopsy. Within one year of the diagnosis of primary sclerosing cholangitis, pulmonary sarcoidosis developed, proven by chest x-ray and transbronchial biopsy. The sarcoidosis initially presented with systemic systems rather than dyspnea. The relationship between primary sclerosing cholangitis, sarcoidosis and the symptomatology are discussed. Concomitant primary sclerosing cholangitis and sarcoidosis may be more common than previously anticipated and could be a further manifestation of disordered immune regulation.


2013 ◽  
Vol 8 ◽  
Author(s):  
Fatih Ors ◽  
Seyfettin Gumus ◽  
Mehmet Aydogan ◽  
Sebahattin Sari ◽  
Samet Verim ◽  
...  

Background: Chest-X-ray has several limitations in detecting the extent of pulmonary disease in sarcoidosis. It might not reflect the degree of pulmonary involvement in patients with sarcoidosis when compared to computed tomography of the thorax. We aimed to investigate the HRCT findings of pulmonary sarcoidosis and to find out the existence of possible relations between HRCT findings and PFTs. In addition, we aimed to investigate the accordance between HRCT findings and conventional chest-X-ray staging of pulmonary sarcoidosis. Method: 45 patients with sarcoidosis with a mean age 29.7+/− 8.4 years were evaluated. Six of them were female and 39 were male. The type, distribution and extent of the parameters on HRCT/CTs were evaluated and scored. Chest-X-rays were evaluated for the stage of pulmonary sarcoidosis. Correlations were investigated between HRCT/ CT parameter scores, Chest X-Ray stages and pulmonary function parameters. Results: Nodule, micronodule, ground glass opacity and consolidation were the most common HRCT findings. There were significant correlations between pulmonary function parameters, HRCT pattern scores, and chest-X-ray stages. A significant correlation between chest-x-ray score and total HRCT score was found. Conclusions: Pulmonary sarcoidosis patients might have various pulmonary parenchymal changes on HRCT. Thorax HRCT was superior to chest-X-ray in detecting pulmonary parenchymal abnormalities. The degree of pulmonary involvement might be closely related to the loss of pulmonary function measured by PFTs. Chest-X-ray is considered to have a role in the evaluation of pulmonary sarcoidosis.


Praxis ◽  
2019 ◽  
Vol 108 (15) ◽  
pp. 991-996
Author(s):  
Ngisi Masawa ◽  
Farida Bani ◽  
Robert Ndege

Abstract. Tuberculosis (TB) remains among the top 10 infectious diseases with highest mortality globally since the 1990s despite effective chemotherapy. Among 10 million patients that fell ill with tuberculosis in the year 2017, 36 % were undiagnosed or detected and not reported; the number goes as high as 55 % in Tanzania, showing that the diagnosis of TB is a big challenge in the developing countries. There have been great advancements in TB diagnostics with introduction of the molecular tests such as Xpert MTB/RIF, loop-mediated isothermal amplification, lipoarabinomannan urine strip test, and molecular line-probe assays. However, most of the hospitals in Tanzania still rely on the TB score chart in children, the WHO screening questions in adults, acid-fast bacilli and chest x-ray for the diagnosis of TB. Xpert MTB/RIF has been rolled-out but remains a challenge in settings where the samples for testing must be transported over many kilometers. Imaging by sonography – nowadays widely available even in rural settings of Tanzania – has been shown to be a useful tool in the diagnosis of extrapulmonary tuberculosis. Despite all the efforts and new diagnostics, 30–50 % of patients in high-burden TB countries are still empirically treated for tuberculosis. More efforts need to be placed if we are to reduce the death toll by 90 % until 2030.


Sign in / Sign up

Export Citation Format

Share Document